Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.

Blood - 5 Sept 2024

Woyach Jennifer A, Jones Daniel, Jurczak Wojciech, Robak Tadeusz, Illés Árpád, Kater Arnon P, Ghia Paolo, Byrd John C, Seymour John F, Long Susan, Mohamed Nehad, Benrashid Samon, Lai Tzung-Huei, De Jesus Gary, Lai Richard, de Bruin Gerjan, Rule Simon, Munugalavadla Veerendra

Abstract excerpt

ABSTRACT: Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations. Using peripheral blood samples from patients with relapsed/refractory CLL in ELEVATE-RR (NCT02477696; median 2 prior therapies), we report clonal evolution data for patients progressing on acalabrutinib or ibrutinib (median...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38754046
DOI: 10.1182/blood.2023023659
PMCID: PMC11406168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.PMID 38754046Read ↗

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE studySemantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformationSemantic proximity Read ↗

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.Semantic proximity Read ↗

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.Semantic proximity Read ↗

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaSemantic proximity Read ↗

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.Semantic proximity Read ↗

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.